ArticleEuropean journal of epidemiology2022
Incidence of Parkinson's disease in French women from the E3N cohort study over 27 years of follow-up.
Article in European journal of epidemiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- Revisiting the Association Between Calcium Channel Blockers and Parkinson's Disease in the E3N Cohort.Movement disorders : official journal of the Movement Disorder Society · 2026Article
- Adherence to the Mediterranean and Mediterranean-Dietary Approaches to Stop Hypertension Intervention for Neurodegenerative Delay (MIND) Diets and Parkinson's Disease Incidence in Women: Results from the Prospective E3N Cohort.Annals of neurology · 2026Article
- Comparative Analysis of the Incidence, Prevalence, and Survival of 8 Types of Parkinsonism in a Population-Based Study with 367 Million Person Years of Observation over 21 Years.Movement disorders clinical practice · 2026Observational
- Incidence and spatial variation of Parkinson's disease in the Netherlands (2017-2022): a population-based study.The Lancet regional health. Europe · 2026Article
- Decline of Parkinson's Disease Incidence in Israel: The Value of Cohort Analysis.Neuroepidemiology · 2026Article
- Use of β-adrenoreceptor drugs and Parkinson's disease incidence in women from the French E3N cohort study.Journal of Parkinson's disease · 2025Article
- The Expanding Burden of Neurodegenerative Diseases: An Unmet Medical and Social Need.Aging and disease · 2024Review
- Consumption of milk and other dairy products and incidence of Parkinson's disease: a prospective cohort study in French women.European journal of epidemiology · 2024Article
- Update: Descriptive epidemiology of Parkinson disease.Parkinsonism & related disorders · 2024Review
- The epidemiology of Parkinson's disease.Lancet (London, England) · 2024Review
- What is the Parkinson Pandemic?Movement disorders : official journal of the Movement Disorder Society · 2023Article
- Association of Physical Activity and Parkinson Disease in Women: Long-term Follow-up of the E3N Cohort Study.Neurology · 2023Article
- Reproductive characteristics, use of exogenous hormones and Parkinson disease in women from the E3N study.Brain : a journal of neurology · 2023Article
- Towards a European "Cohort Moonshot": revisiting the long-term strategy to support health research of tomorrow.European journal of epidemiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
Parkinson's disease (PD) is an uncommon disease with a long prodromal period and higher incidence in men than women. Large cohort studies of women with a long follow-up are needed. Within the E3N French cohort study (98,995 women, 40-65 years at baseline), we identified 3,584 participants who self-reported PD or used anti-parkinsonian drugs over 27 years (1992-2018). We obtained medical records to validate PD diagnosis (definite, probable, possible, no). When medical records were not available, we used a validated algorithm based on drug claims to predict PD status. We retained a PD diagnosis for 1,294 women (medical records, 62%; algorithm, 38%). After exclusion of prevalent/possible cases, cases without age at diagnosis, and women lost to follow-up, our analyses included 98,069 women, of whom 1,200 had incident PD (mean age at diagnosis = 71.8 years; incidence rate = 0.494/1,000 person-years). Age-adjusted incidence rates increased over the six first years of follow-up, possibly due to healthy volunteer bias, and remained stable thereafter, similar to incidence rates in women from Western Europe. Forty three percent of PD cases occurred after 20 years of follow-up (2012-2018). The cumulative incidence of PD from 50 to 90 years was 2.41% (95% confidence interval [CI] = 2.27-2.65). PD incidence was lower in ever than never smokers (hazard ratio = 0.86, 95% CI = 0.76-0.96). In conclusion, we estimated PD incidence rates in French women over a 27-year follow-up, and showed stable incidence between 2002 and 2018. The long follow-up and large sample size make this study a valuable resource to improve our knowledge on PD etiology in women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.